Sign Out
Endophthalmitis: Intravitreal injections, including those with Aflibercept (Eylea), have been associated with endophthalmitis (see Adverse Reactions). Proper aseptic injection technique must always be used when administering Aflibercept (Eylea).
Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay and should be managed appropriately.
Increase in intraocular pressure: Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection, including with Aflibercept (Eylea) (see Adverse Reactions). Special precaution is needed in patients with poorly controlled glaucoma. In all cases, both the intraocular pressure and the perfusion of the optic nerve head must therefore be monitored and managed appropriately.
Effects on ability to drive or use machines: Patients may experience temporary visual disturbances after an intravitreal injection with Aflibercept (Eylea) and the associated eye examinations. They should not drive or use machines until visual function has recovered sufficiently.
